Zydena (udenafil)
Zydena’s udenafil identity, Dong-A ST’s international product record, clinical research and the distinction between market presence and local registration.
- Active ingredient
- Udenafil
- Form
- Tablet
- Company
- Dong-A ST (current company product listing)
Zydena is the original udenafil brand developed by Dong-A in South Korea. Dong-A ST’s current international business page also lists Zydena exports to Ukraine, Malaysia and Jordan. A company announcement describes a Russian launch in 2009. The statement that the brand has only ever been available in South Korea is therefore too narrow.
Market presence is not a local registration check
The international product page is evidence of company-reported market presence. The Russian announcement is historical launch evidence. Neither establishes today’s authorization, stock or supply conditions in every named country.
The amounts shown in the structured record describe amounts investigated in trials. A studied 200 mg amount should not be assumed to describe every supplied Zydena pack or its local prescribing instructions.
What the clinical evidence adds
In a randomized 12-week study, 165 men with ED who were taking antihypertensive medicines received udenafil or placebo. The erectile-function questionnaire improved more in both udenafil groups. The ingredient article gives the results and explains why those selected patients do not establish safety for every cardiovascular condition or medicine combination.
Udenafil’s time to peak blood concentration and half-life describe a different exposure pattern from sildenafil or tadalafil. They are not guaranteed erection durations, and daily-treatment research is a different question from the instructions for an as-needed product.
Zydena and Zudena
Zudena is a separately documented Sunrise Remedies product. The similar spelling and shared ingredient do not make its company record the same as Zydena’s, or transfer a particular local authorization between the brands. Compare exact product identities before comparing clinical expectations.
Product record
- Company
- Dong-A ST (current listing); developed by Dong-A Pharmaceutical
- Strengths
- Udenafil 100 and 200 mg (clinical trial doses)
- Market
- Developed in South Korea; company lists exports to Ukraine, Malaysia and Jordan, with historical Russian launch
- Treatment area
- Erectile dysfunction (ED)
- Record reviewed
- 4 October 2026; source retrieval dates are retained with the evidence
Company-reported presence and trial amounts do not establish current local authorization, availability or the contents of a supplied pack.
About udenafil
Udenafil was developed in South Korea; Dong-A ST also lists exports to several countries. Its research half-life describes blood exposure, not guaranteed sexual duration. Company-reported presence does not replace a current local product record.
Using a PDE5 inhibitor safely
Never take a PDE5 inhibitor with nitrates, recreational nitrites (“poppers”) or riociguat, and do not combine two ED medicines. Seek urgent medical help for chest pain, an erection lasting more than four hours, or sudden loss of vision or hearing.
Common side effects include headache, flushing, indigestion and a blocked nose.
Sources
5 sources
Checked .
- The Use of Vasoactive Drugs in the Treatment of Male Erectile Dysfunction: Current Concepts (J Clin Med, 2020) — Europe PMC
- Udenafil: efficacy and tolerability in the management of erectile dysfunction (Ther Adv Urol, 2013) — Europe PMC
- The efficacy and safety of udenafil [Zydena] in hypertensive men (J Sex Med, 2009) — Europe PMC
- International product and export table — Dong-A ST
- Historical Zydena launch in Russia — Dong-A ST